TT-702 is under clinical development by Teon Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TT-702’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TT-702 overview

TT-702 is under development for the treatment of solid tumor, metastatic castration resistant prostate cancer, triple negative breast cancer, melanoma and colorectal cancer. It is administered through oral route. The drug candidate acts by targeting adenosine receptor A2b.

Teon Therapeutics overview

Teon Therapeutics, is a biopharmaceutical company that discovers and develops small molecule drugs for cancer immunotherapy, cardiovascular and metabolic diseases. The company is headquartered in United States.

For a complete picture of TT-702’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.